Asthma Pharmacogenomics

Gregory A. Hawkins; Scott T. Weiss; Eugene R. Bleecker

doi:10.1016/j.iac.2005.09.004

Asthma Pharmacogenomics

Gregory A. Hawkins, Scott T. Weiss, Eugene R. Bleecker

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

It is expected that future treatments will be preceded by genetic tests to prescribe the most effect asthma medication while lowering the risk of adverse side effects. However, it will not be necessary to describe all the genetic determinants affecting drug response to apply pharmacogenomics to asthma therapy. Whether pharmacogenomics becomes common practice may not depend on the availability of tests, but on factors such as affordability, ease of application, and ease of interpreting the results.

Original language	English (US)
Pages (from-to)	723-742
Number of pages	20
Journal	Immunology and Allergy Clinics of North America
Volume	25
Issue number	4
DOIs	https://doi.org/10.1016/j.iac.2005.09.004
State	Published - Nov 2005
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.iac.2005.09.004

Cite this

@article{95cf25bf59a746159e35aed29f5f79b0,

title = "Asthma Pharmacogenomics",

abstract = "It is expected that future treatments will be preceded by genetic tests to prescribe the most effect asthma medication while lowering the risk of adverse side effects. However, it will not be necessary to describe all the genetic determinants affecting drug response to apply pharmacogenomics to asthma therapy. Whether pharmacogenomics becomes common practice may not depend on the availability of tests, but on factors such as affordability, ease of application, and ease of interpreting the results.",

author = "Hawkins, {Gregory A.} and Weiss, {Scott T.} and Bleecker, {Eugene R.}",

year = "2005",

month = nov,

doi = "10.1016/j.iac.2005.09.004",

language = "English (US)",

volume = "25",

pages = "723--742",

journal = "Immunology and Allergy Clinics of North America",

issn = "0889-8561",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Asthma Pharmacogenomics

AU - Hawkins, Gregory A.

AU - Weiss, Scott T.

AU - Bleecker, Eugene R.

PY - 2005/11

Y1 - 2005/11

N2 - It is expected that future treatments will be preceded by genetic tests to prescribe the most effect asthma medication while lowering the risk of adverse side effects. However, it will not be necessary to describe all the genetic determinants affecting drug response to apply pharmacogenomics to asthma therapy. Whether pharmacogenomics becomes common practice may not depend on the availability of tests, but on factors such as affordability, ease of application, and ease of interpreting the results.

AB - It is expected that future treatments will be preceded by genetic tests to prescribe the most effect asthma medication while lowering the risk of adverse side effects. However, it will not be necessary to describe all the genetic determinants affecting drug response to apply pharmacogenomics to asthma therapy. Whether pharmacogenomics becomes common practice may not depend on the availability of tests, but on factors such as affordability, ease of application, and ease of interpreting the results.

UR - http://www.scopus.com/inward/record.url?scp=27644532275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644532275&partnerID=8YFLogxK

U2 - 10.1016/j.iac.2005.09.004

DO - 10.1016/j.iac.2005.09.004

M3 - Review article

C2 - 16257635

AN - SCOPUS:27644532275

SN - 0889-8561

VL - 25

SP - 723

EP - 742

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

IS - 4

ER -

Asthma Pharmacogenomics

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this